Xenobiotic metabolomics: Major impact on the metabolome

Annual Review of Pharmacology and Toxicology

Volumn 52, Issue , 2012, Pages 37-56

  Johnson, Caroline H ^a   Patterson, Andrew D ^b   Idle, Jeffrey R ^c   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Gut microflora; Interindividual variation; Mass spectrometry; Metabotype; Pharmacometabolomics; UPLC

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; ACYLTRANSFERASE; AMINOFLAVONE; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARECOLINE; AROMATIC HYDROCARBON RECEPTOR; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIGOXIN; ESTROGEN; FENOFIBRATE; GESTAGEN; GLUCURONOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; IFOSFAMIDE; MELATONIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; PROBIOTIC AGENT; SULFOTRANSFERASE; THIOTEPA; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; CHEMICAL REACTION; CREATININE BLOOD LEVEL; DEPRESSION; DIET; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG METABOLISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; EPIGENETICS; FOOD DRUG INTERACTION; GENE EXPRESSION; GENETIC VARIABILITY; GRAPEFRUIT; HEREDITY; HUMAN; HYPERICUM PERFORATUM; INTESTINE FLORA; KIDNEY DISEASE; LIFESTYLE; LIPID PEROXIDATION; METABOLOME; METABOLOMICS; MICROBIOME; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLLUTANT; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOPHOSPHAMIDE; ENVIRONMENTAL POLLUTANTS; FENOFIBRATE; GENETIC VARIATION; HUMANS; IFOSFAMIDE; METABOLIC DETOXICATION, DRUG; METABOLOME; METABOLOMICS; METAGENOME; PROTEOMICS; XENOBIOTICS;

EID: 84863401504     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134748     Document Type: Article

References (91)

1. Idle JR, Gonzalez FJ. 2007. Metabolomics. Cell Metab. 6:348-51 (Pubitemid 350012005)
2. Oliver SG, Winson MK, Kell DB, Baganz F. 1998. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16:373-78 (Pubitemid 28410425)
3. Fiehn O. 2002. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 48:155-71
4. Mathers JC, Strathdee G, Relton CL. 2010. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 71:3-39
5. Holmes E, Loo RL, Stamler J, BictashM, Yap IK, et al. 2008. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453:396-400 (Pubitemid 351693125)
6. CaiH,Nguyen N, Peterkin V, Yang YS,HotzK, et al. 2010. A humanized UGT1 mousemodel expressing the UGT1A1?28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab. Dispos. 38:879-86
7. PantuckEJ, Kuntzman R, ConneyAH. 1972. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 175:1248-50
8. Ryan DE, Koop DR, Thomas PE, Coon MJ, LevinW. 1986. Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a. Arch. Biochem. Biophys. 246:633-44 (Pubitemid 16072584)
9. Poland A, Knutson JC. 1982. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev. Pharmacol. Toxicol. 22:517-54
10. Johne A, Brockm̈oller J, Bauer S, Maurer A, Langheinrich M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's Wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66:338-45 (Pubitemid 29494126)
11. Hall SD,Wang Z, Huang SM, HammanMA, Vasavada N, et al. 2003. The interaction between St John's Wort and an oral contraceptive. Clin. Pharmacol. Ther. 74:525-35 (Pubitemid 37521996)
12. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. 2011. The effect of grapefruit juice on drug disposition. Expert Opin. Drug Metab. Toxicol. 7(3):267-86
13. Kiani J, Imam SZ. 2007. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr. J. 6:33
14. Johnson CH, Patterson AD, Krausz KW, Lanz C, Kang DW, et al. 2011. Radiation metabolomics: 4. UPLC-ESI-QTOFMS-based metabolomics for urinary biomarker discovery in γ-irradiated rats. Radiat. Res. 175(4):473-84
15. Nell S, Suerbaum S, Josenhans C. 2010. The impact of themicrobiota on the pathogenesis of IBD: lessons from mouse infection models. Nat. Rev. Microbiol. 8:564-77
16. Ley RE. 2010. Obesity and the human microbiome. Curr. Opin. Gastroenterol. 26:5-11
17. Musso G, Gambino R, Cassader M. 2011. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med. 62:361-80
18. Nicholson JK, Holmes E, Wilson ID. 2005. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3:431-38 (Pubitemid 40590386)
19. Wilson ID, Nicholson JK. 2009. The role of gut microbiota in drug response. Curr. Pharm. Des. 15:1519-23
20. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. 1981. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N. Engl. J. Med. 305:789-94 (Pubitemid 11007233)
21. Sekirov I, Tam NM, JogovaM, RobertsonML, Li Y, et al. 2008. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun. 76:4726-36
22. Antunes LC, Han J, Ferreira RB, Lolíc P, Borchers CH, Finlay BB. 2011. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob. Agents Chemother. 55(4):1494-503
23. Romick-Rosendale LE, Goodpaster AM,Hanwright PJ, PatelNB, Wheeler ET, et al. 2009. NMR-based metabonomics analysis ofmouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn. Reson. Chem. 47(Suppl. 1):S36-46
24. Bialonska D, Ramnani P, Kasimsetty SG, Muntha KR, Gibson GR, Ferreira D. 2010. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int. J. Food Microbiol. 140:175-82
25. Martin FP, Wang Y, Sprenger N, Yap IK, Lundstedt T, et al. 2008. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanizedmicrobiomemousemodel. Mol. Syst. Biol. 4:157
26. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, et al. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106:3698-703
27. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK. 2011. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J. Proteome Res. 10:2842-51
28. Lhoste EF,OurietV, Bruel S, Flinois JP, BŕezillonC, et al. 2003. The human colonicmicroflora influences the alterations of xenobiotic- metabolizing enzymes by catechins in male F344 rats. Food Chem. Toxicol. 41:695-702 (Pubitemid 36349551)
29. Bj̈orkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, Pettersson S. 2009. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4:e6958
30. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. 2000. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett. 484:169-74
31. Lindon JC, Nicholson JK. 2008. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 1:45-69
32. Patterson A, Lanz C, Gonzalez FJ, Idle JR. 2010. The role of mass spectrometry-based metabolomics in medical countermeasures against radiation. Mass Spectrom. Rev. 29:503-21
33. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. 2008. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48:653-83 (Pubitemid 351738167)
34. Chan EC,Koh PK,Mal M, Cheah PY, EuKW,et al. 2009. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8:352-61
35. Waldram A, Holmes E, Wang YL, Rantalainen M, Wilson ID, et al. 2009. Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J. Proteome Res. 8:2361-75
36. Marriott P, Shellie R. 2002. Principles and applications of comprehensive two-dimensional gas chromatography. Trends Anal. Chem. 21:573-83
37. Lanz C, Patterson A, Slav́?k J, Krausz K, Ledermann M, et al. 2009. Radiation metabolomics: 3. Biomarker discovery in the urine of γ-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. Radiat. Res. 172:198-212
38. Tyburski JB, Patterson AD, Krausz KW, Slav́?k J, Fornace AJ Jr, et al. 2009. Radiation metabolomics: Dose-and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal γ-radiation exposure in mice. Radiat. Res. 172:42-57
39. Patterson AD, Slanar O, Krausz KW, Li F, Ḧofer CC, et al. 2009. Human urinary metabolomic profile of PPARαinduced fatty acid β-oxidation. J. Proteome Res. 8:4293-300
40. Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, et al. 2011. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J. Biol. Chem. 286:19511-22
41. Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ. 2003. Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun. Mass Spectrom. 17:2632-38 (Pubitemid 37498776)
42. Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ. 2008. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology 149:1869-79 (Pubitemid 351468324)
43. Li F, Patterson AD, Ḧofer CC, Krausz KW, Gonzalez FJ, Idle JR. 2010. Comparative metabolism of cyclophosphamide and ifosfamide in themouse using UPLC-ESI-QTOFMS-basedmetabolomics. Biochem. Pharmacol. 80:1063-74
44. Montoliu I, Martin FP, Collino S, Rezzi S, Kochhar S. 2009. Multivariate modeling strategy for intercompartmental analysis of tissue and plasma 1H NMR spectrotypes. J. Proteome Res. 8:2397-406
45. Liu A, Patterson AD, Yang Z, Zhang X, Liu W, et al. 2009. Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometrybased metabolomics. Drug Metab. Dispos. 37:1157-63
46. Chen C, Krausz KW, Idle JR, Gonzalez FJ. 2008. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 283:4543-59
47. Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ. 2006. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem. Res. Toxicol. 19:818-27 (Pubitemid 43939061)
48. Giri S, Krausz KW, Idle JR, Gonzalez FJ. 2007. Themetabolomics of (±)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem. Pharmacol. 73:561-73 (Pubitemid 46038850)
49. Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, et al. 2007. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem. Res. Toxicol. 20:531-42 (Pubitemid 46548699)
50. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, et al. 2006. Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J. Pharmacol. Exp. Ther. 318:1330-42 (Pubitemid 44268343)
51. Bonzo JA, Patterson AD, Krausz KW, Gonzalez FJ. 2010. Metabolomics identifies novel Hnf1α-dependent physiological pathways in vivo. Mol. Endocrinol. 24:2343-55
52. Li F, Patterson AD, Ḧofer CC, Krausz KW, Gonzalez FJ, Idle JR. 2011. A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem. Pharmacol. 81:1043-53
53. Chen N, Aleksa K, WoodlandC,RiederM,Koren G. 2008. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br. J. Pharmacol. 153:1364-72 (Pubitemid 351481517)
54. Guerre-Millo M, Gervois P, Rasṕe E,Madsen L, Poulain P, et al. 2000. Peroxisome proliferator-activated receptor αactivators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275:16638-42 (Pubitemid 30398891)
55. Blane GF. 1987. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am. J. Med. 83:26-36
56. Cloûatre Y, LeblancM, Ouimet D, Pichette V. 1999. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol. Dial. Transplant. 14:1047-48 (Pubitemid 29155193)
57. Nishimura J, Dewa Y,MugurumaM, Kuroiwa Y, Yasuno H, et al. 2007. Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol. Sci. 97:44-54 (Pubitemid 47072154)
58. Davidson MH, Armani A,McKenney JM, Jacobson TA. 2007. Safety considerations with fibrate therapy. Am. J. Cardiol. 99(6):S3-18 (Pubitemid 46412226)
59. Tahmaz M, Kumbasar B, Ergen K, Ure U, Karatemiz G, Kazancioglu R. 2007. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren. Fail. 29:927-30 (Pubitemid 350125669)
60. Qi C, Zhu YJ, Reddy JK. 2000. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem. Biophys. 32:187-204
61. Peters JM, Cheung C, Gonzalez FJ. 2005. Peroxisome proliferator-activated receptor-αand liver cancer: Where do we stand? J. Mol. Med. 83:774-85 (Pubitemid 41407861)
62. Gonzalez FJ, Shah YM. 2008. PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2-8
63. Weil A, Caldwell J, Strolinbenedetti M. 1990. The metabolism and disposition of 14C fenofibrate in human volunteers. Drug Metab. Dispos. 18:115-20 (Pubitemid 20085660)
64. Weil A, Caldwell J, Strolinbenedetti M. 1988. The metabolism and disposition of fenofibrate in rat, guinea-pig, and dog. Drug Metab. Dispos. 16:302-9
65. Cornu-Chagnon MC, Dupont H, Edgar A. 1995. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 26:63-74
66. Liu A, Chen Y, Yang Z, Feng Y, Rui W, et al. 2009. New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS. Xenobiotica 39:345-54
67. Nicholson JK, Lindon JC, Wilson ID. 2011. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12:103-11
68. ClaytonTA, Lindon JC,Cloarec O, Antti H, CharuelC, et al. 2006. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-77
69. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. 2009. Pharmacometabonomic identification of a significant host-microbiomemetabolic interaction affecting human drugmetabolism. Proc. Natl. Acad. Sci. USA 106:14728-33
70. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. 2010. Use of pharmacometabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88:45-51
71. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, et al. 2011. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomicsinformed pharmacogenomics. Clin. Pharmacol. Ther. 89:97-104
72. Nebert DW, Zhang G, Vesell ES. 2008. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40:187-224 (Pubitemid 352000946)
73. Cheung C, Gonzalez FJ. 2008. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J. Pharmacol. Exp. Ther. 327:288-99
74. Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ. 2011. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 41:112-23
75. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, et al. 2000. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos. 28:1321-26
76. Cho JY, Kang DW, Ma X, Ahn SH, Krausz KW, et al. 2009. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 50:924-37
77. Ma X, Idle JR, Gonzalez FJ. 2008. The pregnane X receptor: from bench to bedside. Expert Opin. Drug Metab. Toxicol. 4:895-908
78. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, et al. 2010. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 335:32-41
79. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, et al. 2007. The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35:194-200 (Pubitemid 46148730)
80. Wang T, Ma X, Krausz KW, Idle JR, Gonzalez FJ. 2008. Role of pregnane X receptor in control of alltrans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 324:674-84 (Pubitemid 351185843)
81. Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, et al. 2009. Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-α. Toxicol. Sci. 110:204-11
82. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, et al. 2004. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α. Cancer Res. 64:3849-54 (Pubitemid 38697295)
83. Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. 2006. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor αto Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27:1074-80
84. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, et al. 2005. Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem. Res. Toxicol. 18:1471-78 (Pubitemid 41361721)
85. Cheung C, Yu AM,Ward JM, Krausz KW, Akiyama TE, et al. 2005. The CYP2E1-humanized transgenic mouse: role of CYP2E1 in acetaminophen hepatotoxicity. Drug Metab. Dispos. 33:449-57 (Pubitemid 40279947)
86. Ma X, Cheung C, Krausz KW, Shah YM, Wang T, et al. 2008. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab. Dispos. 36:2506-12
87. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. 2009. Rifampicin-activated human pregnane Xreceptor andCYP3A4induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 37:1611-21
88. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. 2004. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol. 44:1-25 (Pubitemid 38268090)
89. Chen S, Beaton D, Nguyen N, Senekeo-Effenberger K, Brace-Sinnokrak E, et al. 2005. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J. Biol. Chem. 280:37547-57 (Pubitemid 41642363)
90. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. 2009. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1:6ra14
91. Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, et al. 2007. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 3:112